{"id":177107,"date":"2026-09-30T20:36:18","date_gmt":"2026-09-30T20:36:18","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/177107\/"},"modified":"2026-09-30T20:36:18","modified_gmt":"2026-09-30T20:36:18","slug":"novo-plans-108-job-cuts-at-nj-headquarters","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/177107\/","title":{"rendered":"Novo plans 108 job cuts at NJ headquarters"},"content":{"rendered":"\n<p>Another wave of layoffs is hitting New Jersey\u2019s pharmaceutical sector with Novo disclosing planned workforce reductions.\n<\/p>\n<p>The Danish drugmaker said it expects to cut 108 positions by Dec. 31 at its U.S. headquarters in Plainsboro, according to <a href=\"https:\/\/www.nj.gov\/labor\/assets\/PDFs\/WARN\/2026_WARN_Notice_Archive.pdf\" target=\"_blank\" rel=\"noopener nofollow\">a filing with the New Jersey Department of Labor &amp; Workforce Development.<\/a>\n<\/p>\n<p>A spokesperson for the company told NJBIZ, \u201cLike any business, Novo regularly evaluates its organization to ensure we are positioned to meet evolving market dynamics and patient needs.\u201d\n<\/p>\n<p>\u201cOur focus remains on serving patients, supporting healthcare professionals, and driving sustainable growth in the U.S. We are committed to treating everyone with respect,\u201d they said. \u201cTo protect employee privacy, we will not comment on individual situations.\u201d\n<\/p>\n<p>The downsizing comes a year after Novo launched <a href=\"https:\/\/njbiz.com\/novo-nordisk-9000-job-cuts-restructuring\/\" target=\"_blank\" rel=\"noopener nofollow\">a restructuring campaign aimed at generating about $1.3 billion in savings annually by the end of 2026.<\/a> At the time, the company said it anticipated trimming 9,000 jobs from its 78,400 headcount.<\/p>\n<p><a href=\"https:\/\/beta.earningswhispers.com\/transcript\" target=\"_blank\" rel=\"noopener nofollow\">During the company\u2019s second quarter earnings call in August<\/a>, executives said they are on track to deliver the targeted annualized savings.\n<\/p>\n<p>At the Novo\u2019s Sept. 21 capital markets day in London, CEO Mike Doustdar disclosed that staff departures have reached 13,000. The figure includes the initial 9,000 layoffs and 4,000 subsequent exits, <a href=\"https:\/\/www.fiercepharma.com\/pharma\/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions\" target=\"_blank\" rel=\"noopener nofollow\">according to Fierce Pharma.<\/a> Novo\u2019s headcount now stands at about 67,000.\n<\/p>\n<p>Fueling the future<\/p>\n<p><a href=\"https:\/\/www.biospace.com\/job-trends\/novos-workforce-reduction-climbs-to-13-000-to-fuel-r-d-work\" target=\"_blank\" rel=\"noopener nofollow\">BioSpace reported<\/a> the additional departures \u201cwere not necessarily layoffs.\u201d According to that publication, they included jobs left unfilled as a result of normal attrition, retirements, voluntary departures, decisions not to backfill roles and other changes in hiring decisions.\n<\/p>\n<p>Within New Jersey, <a href=\"https:\/\/njbiz.com\/novo-nordisk-bristol-myers-nj-layoffs\/\" target=\"_blank\" rel=\"noopener nofollow\">Novo let go 263 workers last December.<\/a>\n<\/p>\n<p>Doustdar categorized the companywide reductions as \u201cnot easy\u201d but \u2018necessary.\u201d<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-452381\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/09\/Ozempic_Depositphotos_702045452_L-e1726788767668.jpg\" alt=\"Novo Nordisk is the sole patent holder of semaglutide \u2013 the active ingredient in popular diabetes shot Ozempic and as well as blockbuster weight loss drug Wegovy. The company has said it is not supplied to outside entities.\" width=\"500\" height=\"306\"  \/>Novo Nordisk\u2019s semaglutide injection Ozempic. \u2013 DEPOSIT PHOTOS<\/p>\n<p>\u201cThey were incredibly important, as we\u2019re using the funds coming through this exercise to fuel for the future, fuel the R&amp;D organization, as well as, of course, make ourselves more competitive,\u201d he said.\n<\/p>\n<p>Though Novo\u2019s portfolio includes popular GLP-1 treatments, like type 2 diabetes drug Ozempic and weight management therapy Wegovy, the company has struggled to maintain market share amid increased competition from rival Eli Lilly.\u00a0Novo is also facing the 2032 patent expiration of semaglutide, the key ingredient in Ozempic and Wegovy.\n<\/p>\n<p>In a bid to reassure investors, Novo recently pledged to launch at least five more blockbuster drugs by 2030 and deliver more that $23 billion in pipeline sales in 2035, <a href=\"https:\/\/www.reuters.com\/legal\/litigation\/novo-nordisk-aims-launch-more-than-five-blockbuster-drugs-by-2030-ceo-says-2026-09-21\/\" target=\"_blank\" rel=\"noopener nofollow\">according to Reuters.<\/a>\n<\/p>\n<p><a href=\"https:\/\/njbiz.com\/novo-nordisk-rebrand-novo\/\" target=\"_blank\" rel=\"noopener nofollow\">Novo also just unveiled a rebrand<\/a> designed to make the company more recognizable and consistent.\u00a0Along with an updated version of its Apis bull logo and new slogan, \u201cLasting Health Starts Now,\u201d the company shortened its name from Novo Nordisk to Novo.\n<\/p>\n<p>\t Keep exploring this topic<\/p>\n","protected":false},"excerpt":{"rendered":"Another wave of layoffs is hitting New Jersey\u2019s pharmaceutical sector with Novo disclosing planned workforce reductions. The Danish&hellip;\n","protected":false},"author":2,"featured_media":177108,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[255,406,3845,272,3102,56353,81305,81306],"class_list":["post-177107","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-job-cuts","tag-layoffs","tag-novo","tag-novo-nordisk","tag-ozempic","tag-patent-cliff","tag-warn-notice","tag-workforce-reductions"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117361914540408304","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/177107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=177107"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/177107\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/177108"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=177107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=177107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=177107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}